Nutra Pharma and Agenus Compared: Which Biotech Stock Reigns Supreme?

A deep dive into the financial performance and prospects of these two small-cap medical companies.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Agenus (NASDAQ:AGEN) and Nutra Pharma (OTCMKTS:NPHC) are both small-cap biotech firms, but which one is the better investment? This article compares the two companies across key metrics like profitability, dividends, valuation, earnings, analyst recommendations, risk, and institutional ownership to determine which stock comes out on top.

Why it matters

The biotech sector is highly competitive, with many small players vying for investor attention. Understanding the relative strengths and weaknesses of Agenus and Nutra Pharma can help investors make more informed decisions about where to allocate their capital in this dynamic industry.

The details

Agenus has a stronger consensus rating from analysts and higher potential upside, suggesting they view it as the more favorable investment compared to Nutra Pharma. Agenus also has a higher beta, indicating its share price is more volatile than the broader market, while Nutra Pharma has a lower beta and is less volatile. In terms of financials, Agenus has lower revenue but higher earnings per share than Nutra Pharma. Agenus also outperforms Nutra Pharma on key profitability metrics like net margins, return on equity, and return on assets.

  • The data and analysis in this article is current as of March 8, 2026.

The players

Agenus Inc.

A clinical-stage biotechnology company that discovers and develops immuno-oncology products, including antibody therapies and vaccine adjuvants.

Nutra Pharma Corp.

A biopharmaceutical company that acquires, licenses, and commercializes pharmaceutical products and technologies, as well as homeopathic and ethical drugs for pain management and neurological disorders.

Got photos? Submit your photos here. ›

The takeaway

Based on the comparative analysis, Agenus appears to be the more promising biotech investment of the two, with stronger financial performance, a more favorable analyst consensus, and greater potential upside. However, investors should continue to monitor both companies' progress and developments in the highly competitive and rapidly evolving biotech sector.